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MACROCYCLIC ANTIBIOTICS AS 
SEPARATION AGENTS 
This application is a divisional of U.S. Ser. No. 09/187, 
369 filed Nov. 6, 1998, now U.S. Pat. No. 5,964,996 dated 
Oct. 12, 1999, which, in turn, was a divisional of U.S. Ser. 
No. 08/851,485 filed May 5, 1997, now U.S. Pat. No. 
5,874,005, which, in turn, was a divisional of U.S. Ser. No. 
08/532.581 filed Sep. 29, 1995, now U.S. Pat. No. 5,626,727 
dated May 6, 1997; which, in turn, was an application 
pursuant to 35 USC 371 of PCT/US95/02071, filed Feb. 17, 
1995, which, in turn, was a continuation-in-part of U.S. Ser. 
No. 08/198,409, filed Feb. 22, 1994, now abandoned. 
Antibiotics are a class of chemical compounds which are 
produced by microorganisms, and capable, in a dilute 
Solution, of inhibiting the growth of or destroying bacteria 
and other microorganisms. Today, Some antibiotics are also 
produced Synthetically. Chemically, antibiotics have a wide 
variety of Structures and belong to various groups of com 
pounds. Generally, antibiotics have three names, a chemical 
name, a generic name and a tradename. For example, 
tetracycline, generic name, is 4-dimethylamino-1,4,4a,5.5a, 
6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl 
1,11-dioxo-2-naphthocenecarboxamide, chemical name, 
and is Sold under the tradenames Panmycin and Tetracyn. 
The generic name is generally preferred and will be used in 
the Specification and claims. 
A variety of methods are available for the separation of 
an individual component or chemical compound from fluids. 
Among these methods are distillation, extraction, 
crystallization, precipitation, filtration, electrophoresis and 
various chromatographic techniques. 
Crystallization and precipitation are often batch opera 
tions which entail the addition of an agent to assist in the 
removal of a component from the fluid as a Solid particle. 
Generally, the Solid particles fall to the bottom or rise to the 
top of the fluid. 
Filtration can be either a batch or continuous process and 
includes reverse Osmosis or ultrafiltration and membrane 
permeation. Such processes entail the Selective Separation of 
components from a fluid due to the porosity of a filter. The 
filter itself can be either a fluid or a solid. 
Chromatography, which also operates in either a batch or 
continuous mode, includes liquid chromatography, gas 
chromatography, paper chromatography and thin-layer chro 
matography. Chromatography is based on the differential 
distribution of components between two phases, a mobile 
phase and a Stationary phase. The mobile phase is typically 
a gas or liquid while the Stationary phase is typically a Solid 
or a liquid. Separation occurs because the mobile phase is 
brought into contact with the Stationary phase and caused to 
move past the Stationary phase. Components in the mobile 
phase travel in the mobile phase at different rates depending 
on their affinity for the two phases. 
Electrophoresis involves the motion of electrically 
charged particles in an electric field and comprises applying 
an electric field to a Solution Such that components in the 
solution move by means of the electric field. Electrophoresis 
can be done with free Solutions in the presence of a gel, or 
in the presence of a chromatographic-like Stationary phase 
(the later is Some times referred to as 
electrochromatography). There are a variety of electrophore 
sis techniques. Electrophoresis can be performed in capil 
laries (capillary electrophoresis, CE), in tubes, in slabs, etc. 
Electrophoresis is typically only a batch process. 
A number of these Separation processes employ a chemi 











has been targeted for Separation. Typically, these chemical 
agents, i.e. Separation agents, are either added to the fluid 
phase So as to combine with the targeted compound and 
assist or effect the Separation of the targeted compound, or 
the Separation agent is fixed to a Stationary phase and 
interacts with the targeted compound as it passes by the fixed 
Separation agent thereby assisting or effecting the Separation 
of the targeted compound. 
When using crystallization or precipitation, the Separa 
tion agent is typically added to the fluid Such that it com 
bines with the compound targeted for Separation and causes 
precipitation or crystallization of a complex of the targeted 
compound and the Separation agent. In a filtration process, 
the Separation agents typically make up part of the filter by 
being either affixed to the filter or contained in the liquid 
which acts as the filter. In the fields of chromatography and 
electrophoresis, the Separation agent is either attached to a 
Solid Support or dissolved in Solution. 
In the past, a number of different materials have been 
used as Separation agents for chromatography and electro 
phoresis. Separation agents which have been affixed to the 
Stationary phase in the field of chromatography include 
amino acids, derivatives of amino acids, proteins, 
cyclodextrins, derivatives of cyclodextrins and derivatives 
of linear or branched carbohydrates. In the field of 
electrophoresis, cyclodextrins and their derivatives have 
been used as Separation agents with a wall immobilized 
chiral stationary phase. More often in the field of 
electrophoresis, the cyclodextrin is dissolved in free Solution 
as are derivatives of cyclodextrin, amino acids, and Soluble 
carbohydrates. The uses of Separation agents in 
crystallization, precipitation, filtration, electrophoresis and 
chromatography is well-known and conventional. 
The use of various Separation agents and Separation 
processes have been employed to Separate optical isomers. 
The configuration of an optical isomer or chiral molecule 
generally determines its biological and pharmacological 
activity and effectiveness. It is not uncommon for one 
enantiomer of a chiral molecule to have a different activity 
from the other enantiomer. It is therefore essential to be able 
to Separate and isolate the one enantiomer from the other. 
Separation agents used to Separate optical isomers are often 
referred to as chiral Selectors. 
It has now been discovered that macrocyclic antibiotics 
can be used as Separation agents in a wide variety of 
Separation processes including crystallization, precipitation, 
filtration, chromatography and electrophoresis. In fact, in 
chromatography and electrophoresis processes, it has been 
found that the macrocyclic antibiotic of the present inven 
tion can Separate certain optical isomers which were here 
tofore unable to be separated using known Separation agents. 
It is both Surprising and unexpected that a macrocyclic 
antibiotic works in Such a wide variety of Separation pro 
ceSSes because these macrocyclic antibiotics are So large. 
Heretofore only Small antibiotics have been Suggested for 
use as a separation agent, see U.S. Pat. No. 5,194,133 issued 
Mar. 10, 1993. The 133 patent does not disclose the use of 
antibiotics for Separation of optical isomers. 
It has been found that the macrocyclic antibiotic of the 
present invention can be used both as a Stationary phase and 
as a mobile phase or Solution additive for chromatography 
and electrophoresis. Specifically, it has been found that the 
macrocyclic antibiotic works as a Stationary phase in chro 
matography and capillary electrophoresis and as a mobile 
phase or Solution additive in capillary electrophoresis, thin 
layer chromatography, and liquid chromatography. It has 
also been found that the macrocyclic antibiotic of the present 
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invention when used as a Stationary phase in chromatogra 
phy is Stable in both normal phase and reverse phase modes 
of operation. Furthermore, it appears that the Selectivity of 
the Stationary phase is different between the two chromato 
graphic modes. Hence, the recognition mechanism in the 
reverse phase is not the same as the recognition mechanism 
in the normal phase. This phenomenon has been found in its 
enantioSelectivity and its chiral recognition mechanism in 
both the normal and reverse phases for chromatography. 
The macrocyclic antibiotic of the present invention, 
when used as a chiral Selector in a Stationary phase, has been 
found to have a greater Stability and a higher capacity than 
the prior art protein based Stationary phases. Unlike proteins, 
macrocyclic antibiotics are not denatured or irreversibly 
changed in enantioselectivity when used in normal phase 
mode. 
It has also been found that closely related macrocyclic 
antibiotics when used as chiral Selectors have Somewhat 
similar but not identical selectivity. This means that if one 
macrocyclic antibiotic gives a partial Separation then there is 
a very good chance that a closely related macrocyclic 
antibiotic will give a baseline Separation under very similar 
and often identical operating conditions. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 illustrates the resolution of bromacil, devrinol and 
coumachlor enantiomers on a HPLC column in reverse 
phase using Vancomycin bonded to a Silica gel, 
FIG.2 illustrates the resolution of N-(3,5-dinitrobenzoyl)- 
alpha-methylbenzylamine and 3-2-(2-bromacetamide) 
acetamide-PROXYL enantiomers on a HPLC column in 
normal phase using Vancomycin bonded to a Silica gel; 
FIG. 3 illustrates the effect of an organic modifier on the 
Separation of 5-methyl-5-phenolhydantoin enantiomer on a 
HPLC column in reverse phase using Vancomycin bonded to 
a Silica gel, 
FIGS. 4A, 4B and 4C illustrate the effect on resolution of 
increased analyte on a HPLC column in reverse phase using 
Vancomycin bonded to Silica gel, and 
FIG. 5 illustrates the effect on resolution by adjusting the 
Solvent, polar verSuS non-polar Solvents, on a HPLC column 
in reverse phase using Vancomycin bonded to Silica gel. 
FIG. 6 illustrates a schematic of a macrocyclic antibiotic 
bonded to a Support; and 
FIG. 7 illustrates a foam Separation apparatus used to 
Separate and enrich enantiomers. 
DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
The macrocyclic antibiotic of the present invention is an 
antibiotic which has at least one macrocyclic ring structure. 
The term macrocyclic ring Structure as used herein means 
that the ring Structure contains at least about 10 members 
and more preferably at least about 15 members. The term 
member as used herein means a single atom. For example, 
a benzene ring is a six-membered ring while anthracene has 
three rings, each of which is a six-membered ring. Neither 
benzene nor anthracene has a macrocyclic ring. On the other 
hand, Vancomycin, which is a macrocyclic antibiotic of the 
present invention, has ten rings, five of which are Six 
membered aromatic rings and not macrocyclic; two non 
aromatic Six-membered rings which are also not macrocy 
clic; and three rings with more than ten members which are 
macrocyclic rings in accordance with the present invention. 











more than one macrocyclic ring, e.g. Vancomycin. Good 
results have been found with a macrocyclic antibiotic having 
from 1 to 4 macrocyclic rings. 
It is not completely understood why the macrocyclic 
antibiotic of the present invention works as a separation 
agent. It is thought that, with respect to the Separation of 
optical isomers, the enantioSeparation is made possible by a 
combination of several different mechanisms which allow 
the macrocyclic antibiotic to form a complex with a targeted 
component. These mechanisms include complexation, 
charge-charge interactions, hydrogen bonding, inclusion in a 
hydrophobic pocket, dipole Stacking, Steric interaction or 
combinations thereof. While all other chiral stationary 
phases avail themselves of the same types of interactions, a 
plurality of these mechanisms is not available in a single 
chiral Selector and in relatively close proximity to one 
another. The plurality of interaction mechanisms of the 
present invention is made possible because the Selectors of 
the present invention have more than one of these interaction 
mechanisms available and because the areas on the macro 
cyclic antibiotic where these interaction mechanisms are 
available are in close proximity to one another. 
AS is known to those of skill in the art, different Separation 
agents have different degrees of effectiveness in Separating 
components. That holds true for the macrocyclic antibiotics 
of the present invention. AS is shown in the following 
examples, certain macrocyclic antibiotics are more effective 
at Separating components than other macrocyclic antibiotics. 
Derivatives of the macrocyclic antibiotic of the present 
invention can also be used as Separation agents in accor 
dance with the present invention So long as the interaction 
mechanisms of the macrocyclic antibiotic are not destroyed. 
It has been found that derivatization of the macrocyclic 
antibiotic changes its selectivity. Derivatization as used in 
the Specification and claims means not only the addition of 
chemical components to the macrocyclic antibiotic but also 
derivatization where a portion of the macrocyclic antibiotic 
has been removed. Where a portion of the macrocyclic 
antibiotic has been removed, at least one of the macrocyclic 
ring Structures must remain intact to allow the macrocyclic 
antibiotic dreivative to function as a Separation agent. For 
instance, it is known that when certain macrocyclic antibi 
otics are bonded to a Support matrix that a portion of the 
macrocyclic antibiotic is lost during the chmeical reaction. 
It is also known that there are methods which can be 
employed in order to prevent the loSS of those portions of the 
macrocyclic antibiotic which are lost during the bonding 
reaction. 
Polymers of macrocyclic antibiotics of the present inven 
tion can also be used as Separation agents in accordance with 
the present invention. 
The term macrocyclic antibiotic as used in the Specifica 
tion and claims means not only the macrocyclic antibiotic 
itself, but also derivatives of macrocyclic antibiotic as 
defined above and polymers of macrocyclic antibiotic. 
Polymers of the macrocyclic antibiotic of the present 
invention can also be used as Separation agents in accor 
dance with the present invention. 
Likewise, it has been found that the macrocyclic antibi 
otic of the present invention can be chemically bonded to a 
Support and function as a separation agent. In bonding the 
macrocyclic antibiotic of the present invention, Some of the 
Structure of the macrocyclic antibiotic can be changed So 
long as the interaction mechanisms of the macrocyclic 
antibiotic are not destroyed. 
Unlike other classes of Separation agents, macrocyclic 
antibiotics comprise a large variety of Structural types 
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including macrocyclic polyene-polyols, ansa compounds (e.g. aliphatic bridged naphthohydroquinones), macrocyclic 
glycopeptides, peptides, peptide-heterocycle conjugates and 
So forth. In general, these compounds have molecular 
weights greater than 600 but less than 2,500 Daltons. There 
are acidic, basic and neutral types. Some cyclic antibiotics 
absorb strongly in the UV and visible spectral regions while 
others are fairly transparent. 
Suitable macrocyclic antibiotics of the present invention 
may be generally classified by their Similarity of chemical 
Structure into the groups of anSamacrollides, macroSlides, 
macrocyclic peptides, which include glycopeptides, and 
polyenes. This list is not exhaustive and there are other 
antibiotics wherein the antibiotic has at least one macrocy 
clic ring which does not fit into one of these four categories. 
The preferred antibiotics are Selected from the group of 
anSamacrollides and macrocyclic peptides, especially glyco 
peptides. 
Ansamacrollides are a family of antibioticS characterized 
by an aliphatic ansa bridge which connects two non-adjacent 
positions on an aromatic nucleus. Ansamacrollides are gen 
erally divided into two groups based on their aromatic 
nucleus. One group contains a naphthoguinone and the other 
a benzoquinone nucleus. The naphthoguinoid ansamycins 
comprise the majority of the known anSamacrollides. Naph 
thoguinoid ansamycins which are useful in the present 
invention include Streptovaricins, rifamycins, tolypomycins, 
halomicins, and naphthomycin. The benzoquinoid anSamac 
rollides which are useful in the present invention include 
geldanamycin and maytansinoids. The preferred anSamac 
rollide is rifamycin and especially rifamycin B. 
Macrollides are a class of antibiotics having a macrocyclic 
ring forming the aglycone often as a 12-, 14- or 
16-membered ring. Macrollides which are useful in the 
present invention include chalcomycin, methymycin, 
neomethymycin, erythromycin, megalomicin, picromycin, 
narbomycin, oleandomycin, triacetyloleandomycin, 
carbomycin, Spiramycin, and tylosin. 
Macrocyclic peptides that are useful in the present inven 
tion include SporideSmollides, capreomycin, ristomycin, 
cyclosporins, tyrocidine, trioStins, gramicidins (gramicidin 
5), tyrocidines, polymyxins, bacitracins, octapeptins, 
actinomycins, etamycins, Vernamycins, enniatins, 
Valinomycin, thiostrepton, teichomycin avoparcin, acta 
planins and Vancomycin. The preferred macrocyclic pep 
tides are glycopeptides, and more especially teichomycin 
(teicoplanin), ristomycin, avoparcin, and Vancomycin. 
Thiostrepton is also a preferred peptide. 
The preferred glycopeptides have three (3) or four (4) 
fused rings. There are different numbers and types of Sugars 
attached to the aglycone. Such preferred glycopeptides hav 
ing these 3 or 4 fused rings include Vancomycin, 
teichomycin, ristomycin, avoparcin and actaplanins. It is to 
be understood that teichomycin includes the different teicho 
mycins Such as: 
Teichomycin R 
A-1 (Z)-4 decanoic acid 
A-2 8-methylnonanoic acid 
A-3 n-decanoic acid 
A-4 8-methyldecanoic acid 
A-5 9-methyldecanoic acid 
It is also to be understood that avoparcin includes alpha 











that actaplanins include the various types of actaplanins Such 
S. 
actaplanin R R 
A. mannosylglucose aOSC 
B rhamnosylglucose aOSC 
B glucose aOSC 
B mannosylglucose H 
C rhamnosylglucose H 
G glucose H 
Polyenes have a large lactone ring which contains 3 to 7 
double bonds. The preferred polyenes are amphotericin 
(amphotericin B), candicidin, candidin, dermostatin, fun 
gichromin and nyStatin. 
Other antibiotics which do not fall into one of the four 
general categories listed above, but have a macrocyclic 
Structure and are useful in the present invention include 
aplasmomycin, boromycin, enterobactin and bebeerine. 
The most preferred macrocyclic antibiotics for use in the 
present invention are Vancomycin, rifamycin, teicoplanin, 
avoparcin, and thiostrepton. Of the various rifamycins, rifa 
mycin B is most preferred. Vancomycin is an amphoteric 
glycopeptide produced by the bacteria Streptomycin Orien 
tallis. Rifamycin B is one of the most common members of 
the family of rifamycin antibiotics and is obtained from the 
bacteria Nocardia mediterranei. Thiostrepton is obtained 
from the micro-organism Streptomyces azureus. Teichomy 
cin is produced by the bacteria Actinoplanes teichomyceti 
CS. 
The macrocyclic antibiotics of the present invention can 
be obtained from any conventional Source and are in many 
cases commercially available. Suitable derivatives of mac 
rocyclic antibiotics for use in the present invention are made 
in any conventional manner using conventional reactants. 
Suitable derivatives include hydroxypropyl derivatives 
made with propylene oxide, acetyl derivatives made with 
acetic anhydride, (R)- or (S)-naphthylethylisocyanate 
derivatives, 3,5-dimethylphenylisocyanate derivatives, 2,6- 
dimethylphenylisocyanate derivatives, as well as others. 
Polymers of the macrocyclic antibiotic which can be used 
in the present invention include homopolymers, derived 
from a Single monomer, or mixed polymers, derived from 
more than one monomer. Such polymers are made in a 
conventional manner using conventional equipment. 
Typically, a crosslinking agent is used to chemically bond 
one macrocyclic antibiotic to another. 
In Stationary phase application, the macrocyclic antibiotic 
of the present invention is affixed to a Support in a conven 
tional manner. Suitably, the macrocyclic antibiotic of the 
present invention is affixed to a Support by either coating a 
Support or chemically bonding the macrocyclic antibiotic to 
the Support. 
The coating of the macrocyclic antibiotic of the present 
invention on a Support is done in a conventional manner 
using conventional equipment. One Suitable means for coat 
ing Silica gel entails using macroporous Spherical Silica gel 
particles and Silanizing these particles with a large excess of 
dichlorodiphenyl Silane and triethylamine at refluxing tem 
perature in toluene. The Silanized Silica gel is then coated 
with the macrocyclic antibiotic. The coated Silica gel is used 
in a conventional column. In the case of coating a Silica gel, 
polymers or copolymers of the macrocyclic antibiotic are 
preferred as they are not easily removed during Separation 
procedures. 
The macrocyclic antibiotic is chemically bonded to a 
Support using conventional bonding chemistry, So long as it 
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does not destroy the interaction mechanisms of the macro 
cyclic antibiotic which yields the Separation mechanism of 
the present invention. The chemical bond between the 
Support and the macrocyclic antibiotic forms a leash, bridge 
or spacer between the Support and the macrocylic antibiotic. 
The leash must be long enough So that the macrocyclic 
antibiotic is able to function as a separation agent, yet not So 
long as to dominate the Separation. The order of reaction, 
e.g. Support to leash then Support-leash to macrocyclic 
antibiotic, will be dependent upon the chemistry of the 
Support, leash and macrocyclic antibiotic. FIG. 6 illustrates 
a Schematic of macrocyclic antibiotic 10' bonded to Sup 
port 12 by linkage 14 . 
Suitable Supports for making the Stationary phase in 
accordance with the present invention include inorganic 
materials. Such as Silica gel and alumina, Synthetic polymeric 
materials. Such as polystyrenes, polyurethanes, polyvinyl 
alcohol and polyamides, natural materials. Such as agarose, 
cellulose, dextran and linear and branched amylose. A 
preferred Support is Silica gel. 
In the case of chemically bonding a macrocyclic antibiotic 
to a Silica gel, Suitable bonding of the macrocyclic antibiotic 
to the Support can be by way of a carboxylic acid terminated 
organosilane, an amine terminated oxysilane, epoxy termi 
nated organosilanes and isocyanated terminated organosi 
lanes. Suitable carboxylic acid terminated organosilanes 
include 10-(carbomethoxy)ethylmethyldichlorosilane and 
2-(carbomethoxy)-ethyltrichlorosilane. Suitable amine ter 
minated organosilanes include 3-amino-propyldimethyl 
ethoxysilane and 3-aminopropyltriethoxysilane. Suitable 
epoxy, terminated Silanes include (3-glycidoxypropyl) 
trimethyloxysilane, 3-glycidoxypropyldimethylethoxysilane 
and 3-glycidoxypropyltriethoxysilane. Suitable isocyanated 
terminated organo Silane S include 3-isocyanato 
propyltrie thoxy Silane and 
3-isocyanatopropyldimethylchlorosilane. 
The linkage between the macrocyclic antibiotic and the 
leash includes ether, thioether, amine, amide, carbamate, 
urea, and hydrocarbon. 
In order to form the Stationary phase in accordance with 
the present invention using a carboxylic acid terminated or 
an amine terminated organosilane, dry Silica is slurried with 
dry toluene and a Solution of the organosilane in toluene is 
added dropwise over a period of time and refluxed with the 
toluene Silica gel Slurry. Refluxing is continued over a period 
of time at about 110°C. An amount of macrocyclic antibiotic 
is added along with an appropriate carbodiimide dehydrating 
agent. After allowing the mixture to react for a period of 
time, the Stationary phase is filtered and washed. 
In order to bond the macrocyclic antibiotic of the present 
invention to a Silica gel and an isocyanate terminated 
organosilane, the macrocyclic antibiotic is reacted with a 2 
or 3 molar excess of the organosilane in an anhydrous DMF. 
The reaction product is then added to a dry DMF slurry of 
Silica gel wherein the weight ratio of modified macrocyclic 
antibiotic to Silica gel is about 1:2. The Solution is stirred and 
allowed to react for 20 hours at about 105 C. Subsequently, 
the reaction product is filtered and washed. 
In order to form a Stationary phase using the macrocyclic 
antibiotic of the present invention, Silica gel and an epoxy 
terminated organosilane are reacted in toluene in a conven 
tional manner, see for example U.S. Pat. No. 4,539,399. 
Other Suitable bonding chemistries between the Silica gel 
or glass bead and the macrocyclic antibiotic of the present 
invention include making an O-aminopropyl Silanized Silica 
gel and then using a glutaraldehyde to attach an amino group 











Such a process works where the macrocyclic antibiotic has 
an amino group. 
In the case of a natural Support Such as agarose, cellulose, 
dextran or linear and branched amylose, the macrocyclic 
antibiotic is bonded to the Support in a conventional manner 
using conventional equipment. See, for example, "Affinity 
Chromatography”, Chemical and Engineering NeWS, Aug. 
26, 1985, pages 17-32. 
The Stationary phase employing the macrocyclic antibi 
otic of the present invention also includes encapsulation. 
Encapsulation of the macrocyclic antibiotic of the present 
invention is accomplished using a conventional process in a 
conventional manner to build a porous polymer cage around 
the macrocyclic antibiotic. Such porous polymer cages are 
formed as beads and are then used in columns. The porous 
cage allows the flow of material through the cage while 
preventing the escape of the macrocyclic antibiotic. In this 
way, the macrocyclic antibiotic of the present invention is 
able to function as a separation agent. 
The macrocyclic antibiotic of the present invention is 
used in a conventional manner in a conventional Separation 
process Such as crystallization, precipitation, filtration, elec 
trophoresis or chromatography. 
In crystallization and precipitation, it is added as a sepa 
ration agent to fluid in an amount effective to cause precipi 
tation or crystallization of the targeted component, prefer 
ably in an amount greater than the amount of component in 
Said fluid targeted for Separation, more preferably about 
2-10 times more. 
In a filtration process, the macrocyclic antibiotic is affixed 
to a Solid Support or included as a component in the liquid 
filter. The macrocyclic antibiotic is used in the filtration 
process in a conventional manner With conventional equip 
ment. The amount of macrocyclic antibiotic used in the filter 
is an amount effective to Separate the targeted component. 
In the processes of electrophoresis and chromatography, 
the macrocyclic antibiotic of the present invention is used in 
a conventional manner with conventional equipment as a 
mobile phase additive or affixed to a Support. 
These and other aspects of the present invention may be 
more fully understood by reference to the following 
examples. 
EXAMPLE 1. 
This example illustrates making a Stationary phase of 
macrocyclic antibiotics in accordance with the present 
invention. 
In order to make a Stationary phase, 1.0 g of the macro 
cyclic antibiotic was dried in vacuo over P.O.s at 100° C. for 
four hours. Dried macrocyclic antibiotic was then dissolved 
(using a stirring bar) with 100 ml of anhydrous N,N- 
dimethyl formamide (DMF) in a 500 ml, three-neck round 
bottom flask. The reaction was blanketed with dry N gas. 
Dry N gas was introduced through one neck and initially 
was allowed to Sweep through the apparatus and escaped 
through the Second neck which also was fitted with a 
thermometer using a Standard two neck adapter. The third 
neck of the round bottom flask was equipped with a drop 
ping funnel which had a pressure equalizing Side tube. The 
flask was heated using a heating mantle. When the tempera 
ture of the solution reached 90–95 C., 520 ul of 
3-isocyanatopropyltriethoxysilane which was dissolved in 
20 ml of DMF was added dropwise (at the rate of 10–15 
dropS/min.) while stirring the flask. After adding the reagent, 
the reaction was stirred for 10 hours. These steps produced 
a macrocyclic antibiotic-bonded-to-the-organosilane. Next, 
3.5g of Silica gel (spherical, 5u, 100 A pore size) was dried 
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in vacuo at 100° C. over POs for four hours. The dried silica 
gel was then added to the DMF solution of macrocyclic 
antibiotic-bonded-to-the-organosilane and Stirred and heated 
to 105 C. and allowed to react for 20-24 hours. The mixture 
was then allowed to cool to room temperature, filtered and 
washed with DMF, methanol, toluene, methanol, water and 
methanol. 
This procedure was employed for each of the macrocyclic 





3.5 dimethylphenyl-derivitized vancomycin 
EXAMPLE 2 
This example illustrates the use of various immobilized 
macrocyclic antibiotics as Separation agents in a Stationary 
phase. In this example, liquid chromatography was 
employed as the Separation process to Separate optical 
isomers. The data from this example are reported in Table II 
below for running the column in reverse phase condition. 
TABLE II 
Mobile 
Compounds kb C. Phase pH Column 
1) Coumachlor 3.27 2.O O/90 4.1 Van 
2) Warfarin 1.98 70 Of90 7.0 Van 
2.27 .44 O/90 4.1 Van 
3) Devrinol 1.40 62 O/90 4.1 Van 
4) 5-Methyl-5- O.38 .41 Of90 7.0 Van 
phenylhydantoin O.24 36 O/90 4.1 Van 
5) Proglumide 1.17 .40 Of90 7.0 Van 
1.18 .75 O/90 4.1 Van 
6) C-(1-Aminoethyl)-4- O.39 3O Of90 7.0 Van 
hydroxybenzyl 
alcohol 
7) Bendroflumethiazide 1.58 25 Of90 7.0 Van 
8) Bromacil O.67 .21 Of90 7.0 Van 
9) Idazoxan O.38 .21 Of90 7.0 Rif 
10) 5-Cyano-6-methoxy-3,4- O.32 .21 Of90 7.0 Van 
dihydro-2-pyridone 
11) Pyridoglutethimide O.84 2O Of90 7.0 Van 
12) N-carbamyl-D,L- O.31 2O O/90 4. Van 
phenylalanine 
13) Aminoglutethimide 0.79 15 Of90 7.0 Van 
14) N-benzoyl-alanine O.47 15 O/90 4. Van 
methyl ester 
15) Coumafuryl O.68 15 Of90 7.0 Van 
16) Dansyl-C-amino-n- 3.29 15 O/90 4. Van 
butyric acid 
17) Dansyl-aspartic acid 3.00 15 O/90 4. Van 
18) N-(3,5-dinitrobenzoyl)- 155 15 O/90 4. Van 
phenylglycine 
19) Thioridazine 22.O 15 Of90 7.0 Thio 
20) Dansyl-norleucine 6.17 .14 O/90 4. Van 
21) 5-(4-Hydroxyphenyl)- 0.78 .14 Of90 7.0 Van 
5-phenylhydantoin 
22) Dansyl-serine 2.09 .12 O/90 4. Van 
23) Indapamide 1.35 .12 Of90 7.0 Van 
24) Benzoin methyl ether O.80 .11 Of90 7.0 Van 
25) N-benzoyl-leucine 1.90 10 O/90 4. Van 
The compounds in this table are listed in order of their C-values from 
highest to lowest. 
This is the k of the first eluted enantiomer. 
The mobile phase compositions indicated are thc volume ratios of aceto 
nitrile to 1% triethylammonium acetate buffer. 
The abbreviations for the columns are as follows: Van = vancomycin 
bonded stationary phase, Thio = Thiostrepton bonded stationary phase and 
Rif = rifamycin B bonded stationary phase. 
In order to test the different chiral Stationary phases, 











ventional manner. The columns were made of StainleSS Steel 
and measured 25 cm in length and had an inside diameter of 
0.44 cm. Either a Shimadzu LC 6A liquid chromatograph 
with UV detection (254 nm) and a C-R3A chromatopac data 
Station or a Waters model 590 HPLC with a 745B data 
module was used with the column to obtain the data reported 
in Table II above. Each separation was carried out at a flow 
rate of 1.0 ml per minute and at room temperature (22 C.). 
The columns were run in reverse phase in a conventional 
manner using 5 ul of a dilute Solution obtained from a 
solution of 10 ug dissolved in 1 ml concentrate. The chiral 
Stationary phases were prepared in accordance with 
Example 1 above. 
The Separation factor, alpha, was a measurement of the 
Separation between the eluted peaks. The greater the Sepa 
ration between the peaks, the greater the value of alpha. 
Mathematically, alpha is defined as the ratio of corrected 
retention times of the two peaks being compared, i.e. 
where t'=corrected retention time, t=uncorrected time and 
to-retention time of an unretained compound. Traditionally, 
the longest retained peak time t is put in the numerator So 
that alpha will be greater than 1. An alpha value of 1 means 
that there is no separation (the peaks co-elute). 
The capacity factor of the first eluted enantiomer, k, is the 
ratio of the corrected retention time to the retention time of 
an unretained compound, i.e. k=(t-to)/to. 
FIG. 1 shows the resolution of bromacil, devrinol and 
coumachlor enantiomers in the reverse phase mode of the 
Vancomycin bonded phase column. This run was conducted 
using the apparatus and following the method of this 
example. The mobile phase consisted of a 10/90 mix of 
acetonitrile and 1% triethylammonium acetate buffer at a pH 
of 7. 
It should be noted that enantiomers of 5-cyano-6- 
methoxy-3,4-dihydro-2-pyridene have never been reported 
to have been resolved using a chiral Stationary phase. 
EXAMPLE 3 
This example illustrates the effect of pH on the separation 
of coumachlor and deVrinol using a Vancomycin Stationary 
phase as prepared in Example 1 above. The Separation 
process employed in this example was liquid chromatogra 
phy. The mobile phase was the same as in Example 2 above, 
and the columns were run in the Same manner as Example 




pH k C. Rs k C. Rs 
7.6 1.OO 1.69 1.6 1.15 18O 3.2 
6.2 1.21 1.64 2.1 1.16 1.77 3.3 
5.5 2.OO 1.60 2.7 1.36 1.76 3.5 
4.5 3.OO 1.64 4.1 1.46 1.70 3.6 
3.6 1.65 2.42 3.9 1.19 1.41 3.7 
The values of k and alpha are determined in the same 
manner as in Example 2 above. R=20t-t)/(wi+wal) where 
w and we are the baseline peak widths of the first and 
Second eluted peaks respectively. 
EXAMPLE 4 
This example illustrates the effect of temperature on the 
Separation of proglumide, 5-methyl-5-phenylhydantoin, and 
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N-carbamyl-D,L-phenylalanine. The Separation process 
employed in this example was liquid chromatography. A 
Vancomycin Stationary phase as prepared in Example 1 
above was employed. The mobile phase was the same and 
the column was run in the same manner, reverse phase, as in 
Example 2 above. The pH of the mobile phase was 4.1. The 
results from this experiment are reported in Table IV below. 
The k, alpha and R values are determined in the same 
manner as in Example 3 above. 
Table IV shows that lowering the separation temperature 
increases the retention as well as the Selectivity (i.e. alpha 
value). In most cases it also resulted in enhanced resolution (R). This means that the gain in Selectivity (alpha) was not 
completely offset by the loss in efficiency from the decrease 
in mass transfer that often occurs at lower temperatures. 
TABLE IV 
Temperature ( C.) k C. Rs 
Proglumide 
O 1.33 2.27 3.6 
5 1.33 2.11 3.3 
15 1.31 87 2.4 
22 1.18 .75 2.1 
35 O.93 57 1.8 
45 O.76 .44 1.6 
5-Methyl-5-phenylhydantoin 
O O.35 38 1.5 
5 0.27 36 1.O 
22 O.24 34 1.O 
35 O.24 3O O.9 
45 O.19 32 O.7 
N-Carbamyl-D.L-phenylalanine 
O O.51 39 1.5 
5 O.39 34 1.3 
15 O.38 23 1.O 
22 O.31 2O O.8 
35 0.27 .11 O.7 
45 O.22 OO O 
EXAMPLE 5 
This example illustrates the effect of flow rate on the 
separation of 3a, 5,6-tetrahydrosuccinimidol 3,4-b 
acenaphthen-10-one. The Separation proceSS employed in 
this example was liquid chromatography. A column was 
packed with a Vancomycin Stationary phase as prepared in 
Example 1 above and the mobile phase was a 50:50 (by 
Volume) mix of isopropanol and hexane. Except for the fact 
that the column was run on normal phase, the column was 
run as in Example 2 above. As shown in Table V below, mass 
transfer was minimized by lowering flow rate which 
enhanced resolution, while having no effect on alpha. Alpha 
and R determined in the same manner as Example 4 above. 
TABLE V 
Flow Rate ml/min C. Rs 
OSO 1.31 1.28 
O.75 1.31 1.19 
1.OO 1.27 1.14 
1.50 1.30 1.13 
2.OO 1.29 1.11 
EXAMPLE 6 
This example illustrates the Separation obtained from 











pared in Example 1 above. The Separation proceSS employed 
in this example was liquid chromatography. Except for 
operating the columns in normal phase resolution, the com 
pounds were Separated in the same manner as Example 2 
above. The chromatographic data are reported in Table VI 
below. Alpha and k were determined in the same manner as 
Example 2 above. 
FIG. 2 shows the resolution of N-(3,5-dinitrobenzoyl)- 
alpha-methylbenzylamine and 3-2-(2-bromacetamido) 
acetamide-PROXYL as reported in Table VI below. 
It should be noted that the separation of 3-2-(2- 
bromacetamido)acetamide-PROXYL has not been 
achieved in any other chiral Stationary phases heretofore. 
It should also be noted that separations were only 
achieved with polar organic mobile phases for the last four 
compounds in Table VI below. 
TABLE VI 
Mobile 
Compounds kb C. Phase Column 
1) 5-Methyl-5-phenyl- 2.5O 1.67 50/50 Van 
hydantoin 
2) Mephobarbital O.58 62 50/50 Van 
3) Hexobarbital 0.75 .61 50/50 Van 
4) N-(3,5-dinitrobenzoyl) O.82 1.36 50/50 Van 
C.-methylbenzylamine 
5) Althiazide 5.30 35 65/35 Thio 
6) 1-Benzoyl-2-tert-butyl-3- 2.67 1.35 50/50 Van 
methyl-4-imidazolidinone 
7) N-(3,5-dintrobenzoyl-C- 2.OO 1.33 10/90 Van 
methylbenzylamine 
8) 3-2-(2-Bromoacetamido) 2.63 130 50/50 Van 
acetamido-PROXYL 
9) Mephenytoin 1.64 1.30 10/90 Van 
10) Laudanosine 2.37 13 10/90 Rif 
4.43 .08 40/60 Van 
11) Oxprenolol 6.O7 13 495/5/2/1f Van 
12) Alprenolol 6.O7 O5 495/5/2/1f Van 
13) Propranolol 8.17 .04 495/5/2/1f Van 
The compounds in this table are listed in order of their C-values from 
highest to lowest (except for the last four compounds which use a differ 
ent mobile phase). 
This is thek of the first eluted enantiomer. 
The mobile phase composition represents the volume ratio of isopropanol 
to hexane. 
The abbreviations for the columns are as follows: Van = vancomycin 
bonded stationary phase, Thio = Thiostrepton bonded stationary phase and 
Rif = rifamycin B bonded stationary phase. 
This mobile phase composition represents the volume ratio of 
isopropanol/hexanefacetonitrile. 
These mobile phase compositions represent the volume ratios of 
acetonitrile?methanol/glacial acetic acid/triethylamine. 
EXAMPLE 7 
This example illustrates the use of a derivatized Vanco 
mycin as a Stationary phase to Separate various compounds 
using a liquid chromatography Separation process. The Sta 
tionary phase used in this example was made in accordance 
with Example 1 above. Except for the fact that the column 
was operated in normal phase, the column was operated in 
the same manner as in Example 2 above. Chromatographic 
data for this experiment are reported in Table VII below. 
TABLE VII 
Mobile 
Compounds kb C. Phase Column' 
1) Mephobarbital O.67 2.03 10/90 DMP-Van 
2) 3a,4,5,6-Tetrahydro- 1.46 1.50 50/50 DMP-Van 




Compounds kb C. Phase Column 
succinimido-3,4-b 
acenaphthen-10-one 
3) Hexobarbital O.91 1.45 10/90 DMP-Van 
4) 1-Benzoyl-2-tert-butyl- 1.16 120 50/50 DMP-Van 
3-methyl-4-imidazolidinone 
5) Ftorafur 3.65 1.25 50/50 DMP-Van 
6) N,N'-Bis(O-methyl-benzyl) 3.47 1.15 10/90 DMP-Van 
sulfamide 
7) Hydroxyzine O.29 114 10/90 DMP-Van 
8) Mephenytoin 1.31 1.09 15/85 DMP-Van 
9) Phensuximide 3.11 1.09 15/85 DMP-Van 
10) C-Carbethoxy-Y-phenyl-y- O.7O 1.08 10/90 DMP-Van 
butyrolactone 
11) Glutethimide O.78 1.05 10/90 DMP-Van 
These compounds are listed in order of their C-values (from highest to 
lowest). This is the k of the first eluted enantiomer. 
The mobile phase compositions listed indicate the volume ratios of iso 
propanol to hexane. 
The abbreviation DMP-Van stands for the 3,5-dimethylphenylcarbamate 
derivatized vancomycin bonded CSP. 
EXAMPLE 8 
This example illustrates the effect of organic modifier 
concentrations on the Separation of 5-methyl-5- 
phenolhydantoin enantiomers using a column packed with a 
Vancomycin Stationary phase as prepared in Example 1 
above. The Separation process employed in this example was 
liquid chromatography. 
AS shown in FIG. 3, increasing the concentration of 
acetonitrile modifier from 0 to 50% (by volume) caused the 
retention and enantioselectivity to decrease. At acetonitrile 
concentrations between 50 and 95% (by volume), there is 
little enantioselective retention and the analyte elutes near 
the dead volume of the column. In neat acetonitrile the 
retention increases and enantioselectivity returns. 
FIG.3 plots the reverse phase retention of the first eluted 
and Second eluted enantiomers as a function of mobile phase 
composition. FIG. 3 refers to the first eluted enantiomer 
which is designated by a box while the second eluted 
enantiomer is designated by a blackened circle. The column 
was run in the same manner as in Example 2 above. 
EXAMPLE 9 
This example illustrates the effect of increasing the 
amount of analyte to be separated using liquid chromatog 
raphy as the Separation process. The Separation agent 
employed in this example was a Vancomycin Stationary 
phase made in accordance with Example 1 above. 
FIGS. 4A, 4B and 4C illustrate the different chromato 
grams for a mixture of 5-methyl-5-phenylhydantoin iso 
mers. FIG. 4A illustrates a chromatogram for a 1 lug amount 
of the analyte; FIG. 4B illustrates a chromatogram for 500 
tug of the analyte; and FIG. 4C illustrates a chromatogram 
for 1600 lug of the analyte. The column was run in the same 
manner as in Example 2 above with a mobile phase of neat 
acetonitrile. 
EXAMPLE 10 
This example illustrates the effect of adjusting the ratio of 
polar and non-polar organic Solvents in a mobile phase with 
respect to the Separation of compounds using liquid chro 











organic Solvents were hexane and isopropanol and the 
enantiomers which were resolved were from a mixture of 
methylphenylhydantoin isomers. The column employed had 
a Vancomycin Stationary phase as prepared in Example 1 
above, and the column was run as in Example 2 above 
except it was run in normal phase mode. 
FIG. 5 illustrates the results from this experiment. In FIG. 
5 the square illustrates the first elute and the blackened circle 
the second elute of the enantiomers. It should be noted that 
only a polar organic phase was able to Separate certain of the 
mixtures using this column, See Specifically the last four 
enantiomers in Table VI of Example 6. 
EXAMPLE 11 
This example illustrates using rifamycin B to Separate 
various compounds. The Separation process employed in 
this example was electrophoresis, a Stationary phase com 
prising a fused Silica capillary having the macrocyclic 
antibiotic, rifamycin B, dissolved in Solution for use in 
capillary electrophoresis. The results of the example are 
reported in Table VIII below. 
TABLE VIII 
Compound Rs time u(a) pu(e) 
Terbutaline 3.1 62.5 5.8 1.8 
Isoproterenol 2.3 63.4 5.7 1.8 
Bamethan 1.9 60.1 6.O 2.1 
Metaproterenol 18 59.5 6.O 2.1 
Synephrine 1.7 53.3 6.7 2.8 
Metanephrine 1.6 57.0 6.3 2.4 
Salbutamol 1.5 59.5 6.O 2.1 
Epinephrine 1.5 62.1 5.8 1.9 
Norphenylephrine 1.5 54.6 6.6 2.7 
+-Ephedrine (1S,2R and 1R,2S) 1.4 52.1 6.9 3.0 
Migration times are given in minutes. 
u(a) is the apparent mobility in cm. kV' min'. 
u(e) is the effective mobility in cm”. kV' min'. 
A fused Silica capillary having a 50 um inside diameter, 
375 um outside diameter, and 57.5 cm total length was 
obtained from Quadrex Corporation of New Haven, Conn. 
The capillaries were prepared by burning off the protective 
coating to form a window, inserting into a capillary holder 
and then conditioning the capillary with 0.5 normal potas 
sium hydroxide. 
A Quanta 4000 Capillary electrophoresis apparatus Sup 
plied by Waters and equipped with a 254 nm lamp was used 
for the tests. The distance to the detector in the capillary was 
50 cm (effective capillary length). All analyzed Samples 
were dissolved in distilled water at about 1 mg/mL, filtered 
with 0.45 um nylon filters, and introduced into the capillary 
using electromigration injection for 5 Seconds at 5 kV. The 
tests were run at a voltage of 8 kV and were carried out at 
room temperature (22 C.). 
Enantiomeric resolutions, migration times and apparent 
and effective mobilities of the enantiomers were determined 
using 25 millimolar of rifamycin B in 40% 2-propanol, 60% 
0.1 M phosphate buffer at a pH of 7. 
Apparent mobility, u(a), is determined by the following 
formula: u(a)=(1)/(txE)=(lxL)/(txV) wherein V is the 
applied voltage, l is the effective capillary length (to the 
detector), L is the total capillary length, t is the migration 
time as measured from the Start of the run until detection, 
and E is the electronic field. 
Effective mobility, u(e), is determined by Subtracting the 
mobility of a neutral particle, u(EOF), from the apparent 
mobility, i.e. u(a)-u(EOF). Apparent mobility and effective 
mobility are conventional measurements. 
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EXAMPLE 12 
This example illustrates the effect of the concentration of 
rifamycin B as a separation agent using the Separation 
process of electrophoresis. A column as taught in Example 
11 above and the apparatus and method of Example 11 
above were used for this example. Table IX below shows the 
migration times, apparent mobilities, effective mobilities 
and resolution of the enantiomers. 
TABLE IX 
Compound Rs time At(a) Al(e) 
15 mM Rifamycin B 
Terbutaline 1.1 37.8 9.5 2.4 
Norphenylephrine 0.5 36.2 9.9 2.8 
Metoprolol O.2 39.0 9.2 2.1 
20 mM Rifamycin B 
Terbutaline 1.5 41.7 8.6 2.O 
Norphenylephrine O.7 39.6 9.1 2.4 
Metoprolol O.3 42.2 8.5 1.9 
25 mM Rifamycin B 
Terbutaline 2.O 48.6 7.4 1.7 
Norphenylephrine O.8 45.6 7.9 2.2 
Metoprolol 0.4 49.2 7.3 1.6 
The migration time is given in minutes while the apparent 
mobility, u(a), and effective mobility, u(e), are reported in 
cm2.kV-1.min-1. All separations were done with a buffer of 
70% 0.1 M phosphate and 30% 2-propanol with a pH of 7 
at the indicated amounts of rifamycin B. 
AS can be seen from Table IX above, increasing the 
concentration of rifamycin B tends to increase the migration 
times Somewhat as a result of Small decreases in electro 
phoretic mobility. As shown in Table IX, this significantly 
enhances the enantiomeric resolution. 
EXAMPLE 13 
This example illustrates the effect of pH on rifamycin B 
as a separation agent in electrophoresis. The apparatus and 
method of Example 11 above was used in this example. All 
separations were done using 25 mM rifamycin B in 70% 0.1 
M phosphate and 30%. 2-propanol. The results of this 
experiment are reported in Table X below. 
TABLE X 
Compound Rs time u(a) u(e) Rs time u(a) u(e) 
pH 5.2 pH 6.0 
Terbutaline 0.6 55.0 6.5 2.6 1.8 42.6 8.4 2.5 
Norphenylephrine O.3 45.O 8.O 3.3 O.9 41.1 8.7 2.7 
Metoprolol O.2 58.O 6.2 23 O.4 48.6 7.4 1.5 
pH 7.0 pH 8.0 
Terbutaline 2.0 48.6 7.4 1.7 1.4 49.2 7.3 1.3 
Norphenylephrine 0.8 45.6 7.9 2.2 0.4 46.2 7.8 1.6 
Metoprolol O.4 49.2 7.3 16 O.3 37.4 9.6 1.5 
pH 9.0 
Terbutaline 0.8 34.0 10.5 1.2 
Norphenylephrine 0.0 34.8 10.3 0.5 
Metoprolol O.O 32.8 11.0 13 
The effect of pH on both migration time and enantiomeric 
resolution is more complicated with rifamycin B than with 
other Separation agents Such as cyclodextrin. This is because 
rifamycin B has ionizable functional groups. Therefore, pH 












and molecular recognition properties of both the analyte and 
the chiral selector. Clearly, all of these factors must be 
balanced in order to maximize resolution. AS has been 
shown in Table X, the best resolution for racemic amino 
alcohols is obtained at pH levels near 7, which produces 
intermediate electrophoretic mobilities and migration times. 
EXAMPLE 1.4 
This example illustrates the effect of organic additives on 
the Separation of enantiomers with rifamycin B using elec 
trophoresis. All Separations were done using 20 mM rifa 
mycin B in a solution of 70% 0.1 M phosphate and 30% of 
the organic additives as listed in Table XI below. The pH of 
the Solution containing the rifamycin B was 7. The organic 
additives are listed in Table XI below. All other aspects of 
this example were conducted in accordance with Example 
11 above. 
TABLE XI 
Compound Rs time u(a) u(e) Rs time u(a) u(e) 
Acetonitrile Methanol 
Terbutaline 0.3 18.6 19.3 5.0 0.4 30.0 12.0 3.1 
Norphenylephrine 0.0 17.8 20.2 5.9 O.O 27.3 13.2 4.2 
Metoprolol O.O. 18.8 19.1 4.8 O.O 30.3 11.9 2.9 
Ethanol 1-Propanol 
Terbutaline O.8 41.4 8.7 2.3 1.4 34.2 10.5 2.2 
Norphenylephrine 0.2 39.3 9.1 2.8 0.4 31.8 11.3 2.7 
Metoprolol O.2 43.5 8.3 2O O.2 33.9 10.6 2.0 
2-Propanol + 0.5% methyl 
2-Propanol t-butyl ether 
Terbutaline 1.5 41.4 8.6 2.0 1.4 51.0 7.1 1.1 
Norphenylephrine 0.7 39.6 9.1 2.4 0.7 47.1 7.6 1.6 
Metoprolol O.3 40.2 8.5 1.9 O.3 49.8 7.2 1.O 
AS can be seen in Table XI, the organic modifiers have a 
profound effect on enantiomeric resolution, electrophoretic 
mobilities and migration times. The addition of 2-propanol 
to the Solution tends to enhance enantiomeric resolution 
relative to equivalent volume percents of other organic 
additives. Although the 2-propanol also tends to produce 
longer migration times and lower electrophoretic mobilities, 
Some of the organic modifiers that produce comparable or 
longer migration times did not produce equivalent enanti 
oSelectivity Separations. 
EXAMPLE 1.5 
This example illustrates the effect of 2-propanol concen 
trations on Separation of enantiomeric compounds using 
electrophoresis as the Separation process. The apparatus and 
method as described in Example 11 above was used in order 
to obtain the chromatographic data in Table XII below. All 
Separations were done using a 0.1 M phosphate at a pH of 
7 at the indicated Volume percent of 2-propanol. The amount 
of rifamycin B used in each of the Separations is also 
indicated below in Table XII. 
TABLE XII 
Compound Rs time At(a) Al(e) 
(A) 20 mM Rifamycin B 
10% 2-Propanol 
Terbutaline O.O 21.0 17.1 3.4 
Norphenylephrine O.O 18.9 19.0 5.1 
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TABLE XII-continued 
Compound Rs time At(a) Al(e) 
Metoprolol O.O 20.7 17.4 3.3 
20% 2-Propanol 
Terbutaline 0.5 29.4 12.2 2.8 
Norphenylephrine O.O 27.3 13.2 3.7 
Metoprolol O.O 30.6 11.7 2.4 
30% 2-Propanol 
Terbutaline 1.5 41.7 8.6 2.O 
Norphenylephrine O.7 39.6 9.1 2.4 
Metoprolol O.3 42.2 8.5 1.9 
(B) 25 mM Rifamycin B 
30% 2-Propanol 
Terbutaline 2.O 48.6 7.4 1.7 
Norphenylephrine 1.O 45.6 7.9 2.2 
Metoprolol 0.5 49.2 7.3 1.6 
40% 2-Propanol 
Terbutaline 3.1 62.5 5.8 18 
Norphenylephrine 1.5 54.6 6.6 2.7 
Metoprolol O.8 62.1 5.8 1.9 
AS can be seen above, the data in Table XII shows that a 
low 2-propanol concentration has no enantio-resolution of 
any of the analyte tested. AS the concentration of organic 
modifier increased, the electrophoretic mobilities decreased, 
the migration times increased, the electro-osmotic flow 
decreased, and the enantio-Separation is enhanced. 
EXAMPLE 16 
This example illustrates the effect of sodium chloride on 
the separation of enantiomers with rifamycin B. All sepa 
rations were done using a 25 mM rifamycin B solution in 
70% 0.1 M phosphate and 30%. 2-propanol solution at a pH 
of 6. The apparatus and method of Example 11 above was 
employed for obtaining the chromatographic data reported 
in Table XIII below. 
TABLE XIII 
Compound Rs time At(a) Al(e) 
O MNaCl 
Terbutaline 18 42.6 8.4 2.5 
Norphenylephrine O.9 41.1 8.7 2.7 
Metoprolol 0.4 48.6 7.4 1.5 
O.OS M NaCl 
Terbutaline 1.4 52.2 6.9 2.O 
Norphenylephrine O.8 45.9 7.8 2.9 
Metoprolol O.3 55.2 6.5 1.6 
O.1O MNaCl 
Terbutaline 1.1 54.3 6.6 1.6 
Norphenylephrine O.7 46.2 7.8 2.8 
Metoprolol O.2 57.6 6.2 1.3 
AS can be seen, increasing the ionic Strength uniformly 
decreased enantiomeric resolution even though migration 
time increased and electrophoretic mobilities decreased. AS 
can be seen, increasing the ionic strength produced very 
Similar effects to increasing the concentration of 2-propanol 
with respect to migration times and electrophoretic mobili 
ties. In both cases, migration times increased, while elec 
trophoretic mobilities decreased. 
EXAMPLE 1.7 
This example illustrates the effect of buffer concentration 











with rifamycin B in electrophoresis. Using the apparatus and 
method of Example 11 above, all Separations were done with 
20 mM rifamycin B and 70% 0.1 aqueous buffer as indicated 
in Table XIV below and 30%. 2-propanol. As shown in Table 
XIV below, the optimum concentration of phosphate buffer 
appears to be 0.1 M. 
TABLE XIV 
Compound Rs time u(a) u(e) Rs time u(a) u(e) 
0.05 M Phosphate 0.10 M Phosphate 
Terbutaline 1.O 38.1 9.4 2.2 1.5 41.7 8.6 2.0 
Norphenylephrine 0.6 34.5 10.0 3.0 0.7 39.6 9.1 2.4 
Metoprolol O.2 37.8 9.5 1.8 0.3 42.2 8.5 1.9 
0.05 M Boric Acid + 
0.15 M Phosphate 0.05 M Phosphate 
Terbutaline 1.O 45.0 8.0 2.0 11 42.6 8.4 1.9 
Norphenylephrine 0.5 42.3 8.5 2.5 0.2 35.0 10.3 3.0 
Metoprolol O.2 45.3 7.9 1.8 O.1 37.5 9.6 1.9 
EXAMPLE 1.8 
This example illustrates the use of Vancomycinto Separate 
a variety of chiral compounds using capillary electrophore 
Sis. 
The apparatus and method of Example 11 above was used 
with a fused Silica capillary measuring 25 cm to detector 
(32.5 cm total) in length and having an inside diameter of 50 
micrometers. Separations were obtained by using 5 mM 
vancomycin in a 0.1 M phosphate buffer. 
In one series of runs, amino acid derivatives of 
N-hydroxy-Succinimidyl-6-amino quinoline carbamate 
(AQC) were separated. In each run the voltage was +5 kV 
and the pH of the buffer was 7.0. One run entailed separating 
a D.L mix of an O-amino-n-butyric acid derivatized with 
AQC and the other run entailed Separating a D.L mix of a 
phenylalainine derivatized with AQC. Separation of the 
enantiomers was obtained in each case and the respective R. 
values were 9.71 and 8.07. 
Other runs were made with AOC derivatives of the 
protein amino acids and those of many other amino acids. In 
each case Vancomycin was able to resolve the enantiomers. 
The average resolutions of 5-10 were achieved. 
In another Series of runs, enantiomers of dansyl amino 
acid derivatives were separated. In the first two runs the 
voltage was +5 kV and the buffer had a pH of 4.9. The first 
run Separated a mix of dansyl-D,L-methionine while the 
Second run Separated a mix of dansyl-D,L-C.-amino-n- 
butyric acid. Separation of the enantiomers was obtained in 
each case and the respective R values were 19.7 and 20.0. 
In a third run a mix of dansyl-D,L-glutanic acid was 
resolved using a buffer at a pH of 6.0 and a voltage of -5 kV. 
Other runs were made with commercially available race 
mic dansyl derivatized amino acids. Resolution of the enan 
tiomers was achieved with resolutions as high as 15-20 
obtained. 
In yet another run a mix of N-2,4-dinitrophenyl-D,L- 
glutanic acid was resolved using a buffer at a pH of 6.0 and 
a voltage of -5 kV. Other N-2,4-dinitrophenyl amino acid 
derivatives were also resolved. These other derivatives 
included those of ethionine, citrulline, Serine, methionine, 
norleucine, norvaline, C.-amino-n-butyric acid and C.-amino 
n-caprylic acid. 
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Other runs were made using Vancomycin to Separate 
various chiral compounds using the electrophoresis proceSS 
and apparatus of this example. The N-3,5-dinitrophenyl 
derivatives of ethionine, leucine, Serine, phenylalanine, 
tryptophan, methionine, norleucine, norvaline, and 
C.-amino-n-butyric acid were resolved. Respective D.L 
mixes of the alanine, Valine, leucine, phenylalanine, 
methionine and phenylglycine derivatized with N-benzoyl 
groupS and 3,5-dinitrobenzoyl groups were resolved. Vari 
ous D.L mixes of N-carbobenzyloxy amino acids were 
resolved. Various D.L mixes of N-phthalyl and N-phthalyl 
glycoyl amino acids were resolved. Enantiomers of 
ibuprofen, indoprofen, flurbiprofen, carprofen, Suprofen, 
fenoprofen and p-hydroxymandelic acid were resolved. 
Additionally, warfarin and coumachlor, which are neutral 
compounds, were also resolved. 
EXAMPLE 1.9 
This example illustrates the use of a macrocyclic antibi 
otic of the present invention for Separation of chiral mol 
ecules using a thin-layer chromatographic technique. 
The macrocyclic antibiotic, Vancomycin, was used as a 
chiral mobile phase additive for the thin-layer chromato 
graphic (TLC) resolution of 6-aminoquinolyl-N- 
hydroxySuccinimidyl carbamate (AOC) derivatized amino 
acids, racemic drugs and dansyl amino acids. Excellent 
Separations were achieved for most of these compounds in 
the reversed phase mode. Both the nature of the stationary 
phase and the composition of the mobile phase Strongly 
influenced enantiomeric resolution. The best results were 
obtained using diphenyl Stationary phases. Acetonitrile was 
the organic modifier that produced the most effective Sepa 
rations with the shortest development times. The results 
from the various runs are reported in Table XV below. 
TABLE XV 
Conc. Mobile 
Compound Rf Rp2. C. R. (M) Phase 
1. Coumachlor O.14 O.2O 1.4 2.5 0.05 4f6/O 
2. Indoprofen O.58 O.63 1.1 1.6 0.05 4f6/O 
3. Warfarin O.04 O.O6 1.5 1.2 0.04 2/10/O 
4. Bendroflume- O.O2 O.O6 3.0 1.8 O.O5 O.5/8.5/1 
thiazide 
5. AQC-C-amino 0.13 (L) 0.16(D) 1.2 1.9 0.025 2/10/0 
phenylacetic acid 
6. AQC-3-amino-3- 0.12 O.18 1.5 2.5 O.4 2/10/O 
phenylpropinic acid 0.11 O.19 1.7 2.2 O.O25 2/10/O 
7. Dansyl-tryptophan 0.01 (L) 0.03(D) 3.0 1.3 0.04 2/10/0 
8. Dansyl-valine 
9. AQC-leu-leu 0.06 (L) 0.10(D) 1.7 1.5 0.04 2/10/0 
0.04 M, 2/10/0). Rf (D-L) Rs (L-D) C. (DLLD) Rs (DLLD) 
O.O3 O.10 3.3 5.0 
R. (L-L) R (D-D) C. (LDLD) Rs (LDLD) 
O.04 O.24 6.O 11.6 
(0.02 M, 1.5/4.570). Rf (D-L) Rs (L-D) C. (DLLD) Rs (DLLD) 
0.17 O.22 1.3 4.5 
R. (L-L) R (D-D) C. (LDLD) Rs (LDLD) 
O.18 O.42 2.3 18.5 
mobile phase compositions listed indicate the volume ratios of 
acetonitrile/0.6 M NaCl/1% triethylammonium acetate buffer (pH = 4.1). AQC stands for 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate, a 
fluorescent-tagging-agent (see Experimental section). 
All racemic analytes, the Vancomycin, all dansyl amino 
acids and the AOC derivatizing kit which was used to make 
the various derivatives of AOC were obtained from com 
mercial sources. The TLC plates were chemically bonded 
diphenyl-F reversed phase plates (5x20 cm, 250u layer 












The Vancomycin was first dissolved in the 0.6 m sodium 
chloride Solution and placed in an ultraSonic bath for about 
15 minutes. Then the organic modifier (acetonitrile) was 
added to complete the mobile phase mixture. The plates 
were developed at room temperature (22 C.) in 6 (i.d.)x23 
cm cylindrical glass chambers. It took approximately 1-3 
hours to completely develop a 5x20 cm TLC plate. All 
compounds were fluorescent. Spot Visualization was done 
by using a fixed-dual wavelength (254 nm and 365 nm) 
ultraViolet hand lamp. 
The AOC derivatives were obtained in a conventional 
manner, as disclosed in Pawlowska et al., J. 
Chromatography, Vol. 641, p. 257 (1993). Approximately 
100 pmol of each isomeric compound was dissolved in 60 
uL of sodium borate buffer (0.2 M, pH 8.8) in a vial and 
vortexed for several seconds; then 20 till of AQC solution 
was added (3 mg per 1 IL of acetonitrile). The vial was 
heated in an oven for 10 minutes at 50° C. The resulting 
solutions were used in TLC without further purification. 
The diphenyl-type Stationary phase gave the best results 
in terms of low Streaking and good Spot integrity during 
development. The racemates resolved were of three types: 
underivatized pharmaceuticals, AQC-amino acids and dan 
Sylamino acids. When enantiomerically pure Standards were 
available, the retention order was determined as shown in 
Table XV above. The mobile phase generally consisted of 
between 17 and 40 volume percent acetonitrile plus 0.6 M 
NaCl. The salt in the water helped to stabilize the binder 
on the TLC plate. Most of the racemates were better than 
baseline resolved. It should be noted that the retention order 
of all AQC-amino acids and dansylamino acids (for which 
standards were available) were the same. The D-enantiomer 
always had a greater R value than the L-enantiomer. 
It should also be noted that besides providing good 
Separation and enantioselectivity, the Vancomycin also 
maintained a relatively Small spot Size during development. 
EXAMPLE 2.0 
This example illustrates the partial Separation of optical 
isomers using bebeerine and a derivative of Vancomycin by 
gas-liquid chromatography. 
Using a coating Solvent of ethyl ether and dichlo 
romethane and conventional capillary gas-liquid chromatog 
raphy apparatus, the Vancomycin was derivatized with an 
n-butyl or n-hexyl isocyanate. This was done in a conven 
tional manner. The optical isomers for which partial Sepa 
ration were obtained are listed in Table XVI below. 
TABLE XVI 
Compound Oven Temp. (C.) 
Vancomycin 
3-chloro-2-norborn anone 35 + 2/min. 
2-ethoxy-tetrahydrofuran 30 + 1/min. 
methyl-2-chloro-propionate 35 + 1/min. 
B-butyro-lactone 3O 
1.2-epoxyhexane 30 + 1/min. 




C.-methyl-benzyl-amine 40 + 2/min. 
B-butyro-lactone 35 + 2/min. 
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TABLE XVI-continued 
Compound Oven Temp. (C.) 
2-acetyl-5-norborene 35 + 2/min. 
3-chloro-butanone 35 + 2/min. 
3-methyl-cyclohexanol 45 + 2/min. 
Separation was accomplished in a conventional manner 
using conventional capillary gas-liquid chromatography. 
The Separation, however, was only partial. 
EXAMPLE 21 
This example illustrates using a macrocyclic antibiotic of 
the present invention as a separation agent in a precipitation 
proceSS. 
Into a beaker containing 25 ml water and 25 ml of 
acetonitrile and 0.25 grams of indoprofen, the macrocyclic 
antibiotic Vancomycin is added. Such a Solution is Super 
Saturated with the macrocyclic antibiotic by adding Small 
portions of the organic Solvent component. 
The macrocyclic antibiotic complexes with indoprofen 
and causes a precipitate to form. The precipitate is recov 
ered. Next, the recovered precipitate is added to water and 
heated to cause the complex between the macrocyclic anti 
biotic and indoprofen to break. The enantiomerically 
enriched compound is then recovered Separately from the 
macrocyclic antibiotic. The macrocyclic antibiotic is then 
recovered and used again. 
EXAMPLE 22 
This example illustrates using a macrocyclic antibiotic, 
Vancomycin, affixed to Silica gel to obtain resolution of 
Several racemic pyridones. 
Using a conventional HPLC technique and a mobile phase 
of a 10/90 mix of acetonitrile and 1% triethylammonium 
acetate buffer at a pH of 7, the analogues which were 
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This example illustrates the use of rifamycin B in affinity 
chromatography to Separate DNA polymerase from Solution. 
Rifamycin B is affixed to a Silica gel in accordance with 
the present invention. A conventional liquid chromato 
graphic column is packed with the Solid Support of rifamycin 
B bonded to the silica gel. Next, a sample containing DNA 
polymerase is injected into the column. The column is 
operated in a conventional manner using conventional 
equipment in order to obtain Separation of the DNA poly 
CSC. 
EXAMPLE 24 
This example illustrates using ristocetin A as a chiral 
Selector in capillary electrophoresis. 
Enantiomeric resolutions, migration times, and apparent 
and effective mobilities of enantiomers of amino acid 
derivatives, nonsteroidal anti-inflammatory, and carboxylic 
acids Separated with ristocetin. The pH and concentration of 
ristocetin are indicated. The results are reported in Table 
XVIII, below. 
Note this is a powerful Separation technique for anions, 
neutral molecules. It appears to be able to resolve most 
N-derivatized amino acids as well. A few representative 
examples are shown below. 
TABLE XVIII 
Reso 
Compound lution time(1) time(2) u(1) u(2) 
AOC Amino 
Acids' 
Alanine pH 7.0 9.4 8.8(D) 12.6(L) -2.5 -8.0 
Valine bH 7.O 6.O. 10.5 12.6 -5.4 -8.0 
Leucine bH 7.O 5.4 9.5(D) 11.3(L) -3.9 -6.5 
FMOCAmino 
Acids' 
Valine bH 7.O 9.0 12.1 16.6 -3.6 -7.3 
Alanine bH 7.O O4 14.7 15.O -6.0 -6.2 
DOPS (3,4- bH 7.O 13.8 11.4 18.6 -2.8 -8.4 
Dihydroxy 
phenylserine) 
Cirtrulline bH 7.O 2.6 9.1 1.O.O -1.3 -2.8 
Norleucine bH 7.O O.7 7.4 7.6 -3.1 -3.7 
Serine bH 7.O 2.4 10.9 12.1 -4.2 -5.6 
Dansyl Amino 
Acids' 
Valine bH 6.O 2O 13.8 14.6 -5.8 -6.5 




































































































































































time(2) u(1) u(2) 
46.5(L) -13.3 -14.1 
11.O -1.0 -6.2 
33.1 -2.1 -4.3 
2O2 -5.3 -6.1 
13.4 -3.2 -8.8 
5.7 -5.7 -7.3 
5.2(L) -3.0 -6.9 
4.5 -6.1 -6.4 
3.0 -3.8 -5.1 
8.1 -1.3 -5.8 
3.6 -6.3 -9.0 
O.9 -4.9 -6.2 
4.6 -3.9 -4.3 
3.5 -1.0 -9.0 
5.0 -4.0 -4.6 
28.1 -8.8 -9.0 
13.1 -4.8 -5.2 
12.3 -7.4 -7.8 
14.3 -4.4 -6.2 
17.4 -8.1 -8.7 
21.7 -13.2 -13.5 
21.4 -12.6 -13.4 
14.5 -9.4 -9.8 
23.4 -6.9 -7.8 
17.1 -8.0 -11.5 
21.6 -6.7 -7.3 
11.1 -2.3 -6.5 
13.4 -6.2 -9.1 
29.1 -9.1 -9.2 
16.8 -4.7 -5.1 
21.8 -13.4 -13.5 












Compound lution time(1) time(2) u(1) u(2) 
PROXYL 
Folinic Acid' pH 6.0 1.3 14.8 16.8 -10.0 -11.3 
Atrolactic acid pH 6.0 0.4 28.6 29.1 -15.3 -15.4 
"Migration time (in minutes) of the first eluting enantiomer. 
Migration time (in minutes) of the second eluting enantiomer. 
u-(1) and u (2) are the effective electrophoretic mobilities of the first and 
second eluting enantiomer in cm kV' min". 2 mMristocetin added to run buffer. 
5 mM ristocetin added to run buffer. 
2 mMristocetin added to run buffer with 10% 2-propanol. 
82 mM ristocetin added to run buffer with 20% 2-propanol. 
"2 mMristocetin added to run buffer with 30% 2-propanol. 
This is a diastereomeric separation of folinic acid. 
These tests were run with a Quanta 4000 (Waters) capil 
lary electrophoresis apparatus equipped with a fixed wave 
length UV lamp. All chiral Separations were performed 
using a 50 um (i.d.)x32.5 cm (25 cm to detector) fused silica 
capillary obtained from QuadreX Corporation and detected 
at 254 nm. The capillary was prepared daily by conditioning 
with 0.1 M potassium hydroxide for 10 minutes. Next, the 
capillary was purged with distilled water for 5 minutes 
followed by the appropriate concentration and pH of the run 
buffer for an additional 5 minutes. The 0.1 M Sodium 
phosphate buffer Solutions were prepared in a volumetric 
flash and adjusted to the desired pH with sodium hydroxide. 
The ristocetin Solution was prepared in a volumetric flask, 
dissolved in the appropriate phosphate buffer, and degassed 
by Sonication. The aqueous buffer/organic modifier 
(2-propanol) mixture was prepared by volume. All Samples 
were dissolved in distilled water and filtered with a 0.45 um 
nylon Syringe filter from Alltech prior to injection. The run 
Voltage for all Separations was +5 kV. Samples were hydro 
Statically injected for 3 or 5 Seconds. Chiral Separations were 
achieved with solutions of 0.1 mg/mL and at ambient 
temperature (22 C.). All materials used for this test were 
conventional. 
Over 120 racemic compounds have been Separated and 
Table XVIII lists a representative selection of those com 
pounds that were resolved using dilute Solutions of ristocetin 
A. This includes all types of N-blocked amino acids and a 
variety of other acidic or anionic compounds. Nonsteroidal 
anti-inflammatory compounds are particularly easy to 
resolve. The enantioselectivity of ristocetin A appears to be 
Somewhat Similar to that of Vancomycin. However, Several 
chiral compounds containing carboxylic acid functional 
groups were resolved with ristocetin A that could not be 
Separated with Vancomycin. These include: mandelic acid, 
2-methoxy mandelic acid, O-acetylmandelic acid, 
3-methoxymandelic acid, B-phenylactic acid, tropic acid, 
2-bromo-3-methylbutyric acid, 1-benzo cyclobu tene 
carboxylic acid and p-chloromandelic acid among others. 
Ristocetin A appears to be complimentary to rifamycin B 
and heparin (which resolve cationic compounds) when used 
as a CE chiral Selector. 
There are at least four other distinguishing features of 
ristocetin A-based CE Separations compared to previous 
Vancomycin-based separations. First, at all concentrations 
between 2 and 5 mM ristocetin A (without added organic 
co-Solvent modifiers) the separation times were significantly 
less than those obtained using Vancomycin. Separation times 
with Vancomycin as a chiral Selector and using analogous 
conditions were typically between 40 and 70 minutes. 
Second, as will be shown, organic modifiers can be used to 
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Substantially enhance enantioresolutions when using risto 
cetin A, but leSS So with Vancomycin. Third, aqueous Solu 
tions of ristocetin A appear to decompose more slowly than 
those of Vancomycin. Finally, the current cost of Vancomy 
cin is much less than that of ristocetin A. 
EXAMPLE 25 
This example illustrates the effect of ristocetin concen 
tration on the migration times, effective mobilities, and the 
resolution of enantiomers. The run buffer was 0.1 M phos 
phate buffer, pH 6, containing the indicated concentration of 
ristocetin. The results are reported in Table XIX, below. 
These tests were run as in Example 24, above. 
TABLE XIX 
Compound Rs t(1) to 2) teof) u(1) u(2) 
2 mM Ristocetin 
2-(3-chloro- 8.9 11.2 21.4 7.6 -3.1 -10.0 
phenoxy)- 
propionic acid 
Ketoprofen 5.7 12.3 14.3 7.5 -4.4 -6.2 
3-Methoxymandelic 1.5 16.8. 20.2 7.6 -11.5 -13.0 
acid 
1-Benzocyclobutene- 1.1 21.0 22.4 7.5 -13.2 -13.7 
carboxylic acid 
5 mM Ristocetin 
2-(3-chloro- 22.1 11.6 29.3 11.5 -0.2 -8.7 
phenoxy)- 
propionic acid 
Ketoprofen 7.4 15.7 27.5 11.5 -3.8 -5.5 
3-Methoxymandelic 4.7 19.2 29.9 11.5 -5.8 -8.8 
acid 
1-Benzocyclobutene- 1.8 42.5 49.6 11.5 -10.3 -10.9 
carboxylic acid 
"The migration times of the enantiomers, tC1) and t(2), are given in min 
utes 
The time corresponding to the electroosmotic flow, t?eof), is given in 
minutes. Note that a decrease in the eof velocity results in an increase in 
t(eof) 
The effective mobilities, ue(1) and ue (2) are given in cm kV 1 min". 
As shown in Table XIX the concentration of ristocetin A 
in the run buffer can have a significant effect on the CE 
Separation. In general, higher concentrations of the chiral 
Selector produce higher enantioresolutions and longer Sepa 
ration times. The reason for the increase in analyte elution 
time is that higher concentrations of ristocetin tend to slow 
the electroosmotic flow. This is because at these pHs the 
positively charged ristocetin tends to interact with the wall 
of the capillary. Increasing the phosphate buffer concentra 
tions lessens the wall interactions Somewhat. However, there 
is a “trade-off Since increasing buffer concentration also 
increases heat generation, baseline noise and usually 
requires a decrease in the run Voltage. The buffer concen 
tration used throughout this project (i.e., 0.1 M phosphate) 
was a compromise after taking into account all of the 
aforementioned factors. A similar “wall-interaction effect” 
was previously noted for Vancomycin. The wall adsorption 
does not seem to affect the run to run reproducibility as long 
as all experimental conditions are held constant. 
The effective mobilities (u, e) of the analytes (which have 
electromigrations opposite to the direction of the electrooS 
motic flow) decrease with increasing concentration of ris 
tocetin A. This is because a greater amount of the analyte is 
asSociated with the ristocetin A when the concentration of 
the chiral Selector is increased. Hence the improvement in 
the enantiomeric Separations at higher ristocetin A concen 











time of association between the chiral Selector and analytes 
due to mass action and (2) a greater time of association 
between the chiral Selector and analyte due to the decrease 
in the electroosmotic flow. 
EXAMPLE 26 
This example illustrates the effect of pH on the migration 
times, effective mobilities, and resolution of enantiomers 
with ristocetin as a chiral Selector. All Separations were 
performed using 2 mMristocetin in 0.1 M phosphate buffer. 
Table XX, below lists the results obtained. 
TABLE XX 
Compound Rs t(1) to 2) teof) u(1) u(2) 
pH 6 
2-(3-chloro- 8.9 11.2 21.4 7.6 -3.1 -10.0 
phenoxy)- 
propionic acid 
Ketoprofen 5.7 12.3 14.3 7.5 -4.4 -6.2 
3-Methoxymandelic 1.5 16.8. 20.2 7.6 -11.5 -13.0 
acid 
1-Benzocyclobutene- 1. 21.0 22.4 7.5 -13.2 -13.7 
carboxylic acid 
pH 7 
2-(3-chloro- 5. 10.1 13.8 7.5 -4.9 -9.2 
phenoxy)- 
propionic acid 
Ketoprofen 2.6 12.6 13.7 7.5 -8.1 -9.1 
3-Methoxymandelic 1. 18.1 2O2 7.4 -5.8 -6.7 
acid 
1-Benzocyclobutene- O4 21.6 22.O 7.5 -13.4 -13.6 
carboxylic acid 
"The migration times of the enantiomers, tC1) and t(2), are given in min 
utes. 
The time corresponding to the electroosmotic flow, t(eof), is given in 
minutes. Note that a decrease in the eof velocity results in an increase in 
t(eof). 
The effective mobilities, u( ) and u(2) are given in cm kV - 1 min". 
These results were obtained following the procedure in 
Example 26, above. 
Table XX shows the effect of pH on the enantioseparation 
of typical racemic analytes. In general, Somewhat lower pHS 
give better enantioresolution. However, there is a limit to 
this effect Since decreasing the pH will significantly decrease 
electroosmotic flow (thereby increasing analysis times) and 
eventually protonate the analytes making them neutral Spe 
cies. At sufficiently low pHs, these two effects inhibit or 
negate the CE enantioSeparation. 
EXAMPLE 27 
This example illustrates the effect of concentration of 
2-propanol as an organic additive on the migration times, 
effective mobilities and resolution of enantiomers with ris 
tocetin as chiral selector. Table XXI lists the results below. 
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TABLE XXI 
Organic Solvent Compound Rs t(1) to) tEOF) u(1) u(2) 
None 2-(3-Chlorophenoxy)- 5.1 10.1. 13.8 7.5 4.9 9.2 
propionic acid 
Ketoprofen 2.6 12.6 13.7 7.5 -8.1 -9.1 
3-Methoxymandelic acid 1.1 18.1 20.2 7.4 -5.8 -6.7 
1-Benzocyclobutene- O.4 21.6 220 7.5 -13.4 -13.6 
carboxylic acid 
10% 2-Propanol 2-(3-Chlorophenoxy)- 5.8 14.6 21.3 5 -3.0 -6.5 
propionic acid 
Ketoprofen 4.5 19.6 21.8 5 -5.8 -6.7 
3-Methoxymandelic acid 1.8 28.0 33.2 5 -8.3 -9.2 
1-Benzocyclobutene- O.7 40.2 40.6 .5 -10.1 -10.1 
carboxylic acid 
20% 2-Propanol 2-(3-Chlorophenoxy)- 7.6 21.4 30.8 8 -2.7 -6.2 
propionic acid 
Ketoprofen 5.7 26.3 29.8 8 -7.6 -8.4 
3-Methoxymandelic acid 2.3 39.6 47.5 8 -9.7 -10.4 
1-Benzocyclobutene- 11 55.0 57.9 7 -10.9 -11.O 
carboxylic acid 
30% 2-Propanol 2-(3-Chlorophenoxy)- 1O.O 26.6 47.7 4.5 -2.4 -5.1 
propionic acid 
Ketoprofen 5.79 37.6 43.1 4.6 -4.2 - 4.8 
3-Methoxymandelic acid 5.22 63.5 89.6 4.5 -6.0 -6.7 
1-Benzocyclobutene- 1.23 70.1 73.7 4.6 -11.3 -11.6 
carboxylic acid 
All separations were performed using 2 mM ristocetin in 0.1 M phosphate buffer (pH7) 
with the indicated volume percentage of organic solvent. 
"The migration times of the enantiomers, t (1) and t (2) are given in minutes. 
The time corresponding to the electroosmotic flow, t (EOF), is given in minutes. 
Note that a decrease in the EOF velocity results in an increase in t (EOF). 
The effective mobilities, u-(1) and u(2), are given in cm kV 'min'. 
3O 
These results were obtained following the procedure 
outlined in Example 24 above. TABLE XXII 
AS found in the case of another macrocyclic antibiotic Compound t1. t2 Column (rifamycin B) the use of organic modifiers can significantly 5 bromacil 9.6 10.6 Van(1) 
alter enantioresolution in Some cases. The addition of 8.0 9.5 TeiO2) 
2-propanol to the run buffer tended to enhance enantioreso- 4-phenyl-5-cyano-6- 7.9 8.6 Van(3) 
lution for most analytes. Also the organic modifier greatly sty, dihydro-2- 12.6 16.3 Tei) 
increased analyses (elution) times as a result of the decreas- E. 10.3 12.1 Van () 
ing electroosmotic flow Velocity. The effect of enhancing 40 11.6 12.9 TeiO2) 
enantioresolution with added organic modifier varies with warfarin 9.6 11.6 Van() 
the analyte. Eventually a level of organic modifier is reached MES, dro-2 5.4 5.8 VanG) 
that decreases enantioresolution. Also when using hydro- story ,4-dihydro-2- 
organic Solvent mixtures in CE for longer periods of time, 45 4-methyl-5-cyano- 9.4 1.0 Van(3) 
one must take precautions to prevent differential evaporation 6-methoxy-3,4-dihydro- 9.7 2.0 Teic) 
of the solution which will affect reproducibility, analysis 2-pyridone 3 
times, resolution, etc 3,4-diphenyl-5-cyano- 11.4 2.O Van(3) 
s 3 w w 6-methoxy-3,4-dihydro- 8.6 1.6 Teio) 
Ristocetin A can decompose with time in aqueous Solu- 2-pyridone (3) 
Thi lerated at acidi basic pH d 4-cyclohexyl-5- 15.2 6.2 Van tion. IS proceSS IS accelerated all acICIIc or basic plS and 50 cyano-6-methoxy-3, 14.9 20.3 TelC4) 
at elevated temperatures. For example, acid hydrolysis 
removes the Sugars and an amine containing fragment from 
the molecule. Interestingly the degradation product remains 
active against Gram-positive bacteria. However, the overall 
Stability of ristocetin A under typical CE operating condi 
tions (e.g., pHs 5-7 and temperatures 15-25 C.) seems to 
exceed that of Vancomycin. We have used solutions of 
ristocetin A up to 4 weeks provided they are refrigerated 
(~4 C.) overnight or when otherwise not in use. 
EXAMPLE 28 
This example illustrates that closely related macrocyclic 
antibiotics when used as chiral Selectors have Somewhat 
Similar but not identical Selectivity. In this example Vanco 
mycin is compared to teicoplanin as a chiral Stationary 





(The column was a 25 cm x 0.44 cm (i.d.) bonded vancomycin CSP (5 
Aum silica gel). The mobile phase consisted of 10:90 acetonitrile-1% pH 
41 triethylammonium acetate buffer (by volume), 1.0 ml/min. (‘’The column was a 25 cm x 0.44 cm (i.d.) bonded teicoplanin CSP (5 
um silica gel). The mobile phase was the same as the in (1), above. The column was a 25 cm x 0.44 cm (i.d.) bonded vancomycin CSP (5 
Aum silica gel). The mobile phase consisted of 10:90 methanol-1% pH 4.1 
triethylammonium acetate buffer (by volume), 1.0 ml/min. ('The column was a 25 cm x 0.44 cm (i.d.) bonded teicoplanin CSP (5 
tum silica gel). The mobile phase was the same as the in (3). The column was a 25 cm x 0.44 cm (i.d.) bonded vancomycin CSP (5 
Aum silica gel). The mobile phase consisted of 30:70 methanol-1% pH 4.1 
triethylammonium acetate buffer (by volume), 1.0 ml/min. 
The column was a 25 cm x 0.44 cm (i.d.) bonded teicoplanin CSP (5 
pum silica gel). The mobile phase was the same as the in (5). 
(1) The column was a 25 cmx0.44 cm (i.d.) bonded 
vancomycin CSP (5 um silica gel). The mobile phase 
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consisted of 10:90 acetonitrile-1% pH 4.1 triethylammo 
nium acetate buffer (by volume), 1.0 ml/min. 
(2) The column was a 25 cmx0.44 cm (i.d.) bonded 
teicoplanin CSP (5um silica gel). The mobile phase was the 
same as that in (1), above. 
(3) The column was a 25 cmx0.44 cm (i.d.) bonded 
vancomycin CSP (5 um silica gel). The mobile phase 
consisted of 10:90 methanol-1% pH 4.1 triethylammonium 
acetate buffer (by volume), 1.0 ml/min. 
(4) The column was a 25 cmx0.44 cm (i.d.) bonded 
teicoplanin CSP (5um silica gel). The mobile phase was the 
same as that in (3). 
(5) The column was a 25 cmx0.44 cm (i.d.) bonded 
vancomycin CSP (5 um silica gel). The mobile phase 
consisted of 30:70 methanol-1% pH 4.1 triethylammonium 
acetate buffer (by volume), 1.0 ml/min. 
(6) The column was a 25 cmx0.44 cm (i.d.) bonded 
teicoplanin CSP (5um silica gel). The mobile phase was the 
same as that in (5). 
One of the things which has been found with respect to the 
teicoplanin columns is that it does a good job at resolving 
native, underivatized amino acids and Some dipeptides. 
These tests were made using conventional liquid chroma 
tography (HPLC) using identical columns except for the 
bonded macrocyclic antibiotic. 
EXAMPLE 29 
This example illustrates good results obtained using a 
vancomycin as a chiral stationary phase. Table XXIII lists 
the results. 
TABLE XXIII 
Compound to K" K", C. Rs. 
Bendroflumethiazide (1) 2.8 5.0 5.8 16 183 
4-Benzl-2- 2.8 2.46 3.09 26 1.75 
Oxazolidinone (2) 
Bromacil (1) 2.8 2.44 2.78 .14 1.51 
Coumafuryl (3) 2.8 3.13 437 .4 2.96 
Devrinol (4) 2.8 2.7 3.3 .24 2.42 
Fenoterol (5) 2.8 1.45 1.93 33 2.06 
Ketamine (1) 2.8 2.97 3.57 2O 2.30 
Luciferin (6) 2.8 1.73 2.28 32 1.96 
Mephobarbitol (7) 2.8 1.56 1.95 25 2.15 
5-Methyl-5- 1.85 0.78 1.32 69 2.18 
Phenylhydanatoin (8) 
5-Methyl-5- 2.8 1.57 2.13 36 3.0 
Phenylhydanatoin (9) 
Phensuximide (10) 2.8 4.5 4.9 O9 1.67 
Proglumide (11) 2.8 2.31 3.30 43 3.7 
Pyridoglutethimide (12) 2.8 2.8 3.3 .2 18 
3a,4,5,6-Tetrahydro- 2.8 2.8 3.33 .2 1.62 
succinimido 3,4-b 
acenaphthen-10-one (13) 
Warfarin (14) 2.8 2.42 3.14 3O 2.57 
C-Methyl-benzylamine (15) 2.8 3.6 4.2 15 1.47 
Flurbiprofen (16) 2.8 2.47 3.23 22 1.95 
Column Operating Parameters 
(1) Mobile Phase: 10:90 volume ration of tertrahydrofu 
ran to 20 mM ammonium nitrate, pH 5.5 
Flow Rate: 1 ml/min. 
Injection Volume: 1 microliter 
Sample Concentration: 2 mg/ml 
(2) Mobile Phase: 70:30 volume ration of hexane and 
ethyl alcohol 
Flow Rate: 1 ml/min. 











Sample Concentration 2 mg/ml 
(3) Mobile Phase: 10:90 volume ration of tetrahydrofurin 
to 20 mM ammonium nitrate, pH 5.5 
Flow Rate: 1.2 ml/min. 
Injection Volume: 1 microliter 
Sample Concentration: 2 mg/ml 
(4) Mobile Phase: 20:80 volume ration of tetrahydrofuran 
to 0.1% triethylammonium acetate buffer, pH 5. 
Flow Rate: 1 ml/min. 
Injection Volume: 3 microliters 
Sample Concentration: 2 mg/ml 
(5) Mobile Phase: 10:90 volume ratio of tetrahydrofuran 
to 20 mM ammonium nitrate, pH 5.5 
Flow Rate: 1.1 ml/min. 
Injection Volume: 15 microliters 
Sample Concentration: 0.5 mg/ml 
(6) Mobile Phase: 10:90 volume ratio of tetrahydrofuran 
to 20 mM ammonium nitrate, pH 5.5 
Flow Rate: 1.1 ml/min. 
Injection Volume: 6 microliters 
Sample Concentration: 0.5 mg/ml 
(7) Mobile Phase: 25:75 volume ratio of ethyl alcohol to 
hexane 
Flow Rate: 1 ml/min. 
Injection Volume: 30 microliters 
Sample Concentration: 0.1 mg/ml 
(8) Mobile Phase: 100% ethyl alcohol ammonium nitrate, 
pH 5.5 
Flow Rate: 1.5 ml/min. 
Injection Volume: 5 microliters 
Sample Concentration: 4 mg/ml 
Column operated in normal phase 
(9) Mobile Phase: 90:10 volume ratio of tetrahydrofuran 
to 20 mM ammonium nitrate, pH 5.5 
Flow Rate: 1 ml/min. 
Injection Volume: 4 microliters 
Sample Concentration: 3 mg/ml 
Column operated in reverse phase 
(10) Mobile Phase: 70:30 volume ratio of hexane to ethyl 
alcohol 
Flow Rate: 0.5 ml/min. 
Injection Volume: 10 microliters 
Sample Concentration: 4 mg/ml 
(11) Mobile Phase: 10:90 volume ratio of tetrahydrofuran 
to 20 mM ammonium nitrate, pH 5.5 
Flow Rate: 1 ml/min. 
Injection Volume: 3 microliters 
Sample Concentration: 2 mg/ml 
(12) Mobile Phase: 10:90 volume ratio of acetonitrite to 
0.1% of triethylammonium acetone buffer, pH 5.5 
Flow Rate: 1.1 ml/min. 
Injection Volume: 15 microliters 
Sample Concentration: 0.5 mg/ml 
(13) Mobile Phase: 25:75 volume ratio of ethyl alcohol to 
hexane 
Flow Rate: 1 ml/min. 
Injection Volume: 1 microliter 
Sample Concentration: 4 mg/ml 
(14) Mobile Phase: 20:80 volume ratio of tetrahydrofuran 
to 0.1% triethylammonium acetone buffer, pH 5 
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Flow Rate: 1 ml/min. 
Injection Volume: 1 microliter 
Sample Concentration: 4 mg/ml 
(15) Mobile Phase: 90:10 hexane to ethyl alcohol 
Flow Rate: 0.5 ml/min. 
Injection Volume: 1 microliter 
Sample Concentration: 2 mg/ml 
(16) Mobile Phase: 20:80 volume ratio of tetrahydrofuran 
to 20 mM ammonium nitrate, pH 5.5 
Flow Rate: 1 ml/min. 
Injection Volume: 2 microliters 
Sample Concentration: 2 mg/ml 
Column, Column Preparation and Measuring Instruments 
In order to Separate the different enantiomers a Stationary 
phase of Vancomycin or teichomycin and Silica beads (5u) 
was prepared and packed into a stainless Steel column 
measuring 25 cm by 4.6 mm (4.4 cm inside diameter) in a 
conventional manner. A conventional liquid chromatograph 
with a UV detector (254 nm) was used to measure the 
Separation. The columns were run in a conventional manner 
at room temperature (25 C.) and the chart speed was 0.5 
cm/min. 
EXAMPLE 30 
This example illustrates separation via absorption bubble 
technology (e.g. flotation, foam flotation, froth flotation, 
floc-flotation, floc-foam flotation) using macrocyclic antibi 
otics in accordance with the present invention. 
Using the apparatus shown in FIG. 7, sample chamber 10 
is filled with a Sample and chiral Separator 12. In this 
example, acetonitrile and Vancomycin at a concentration of 
12 mg/ml is diluted down to about 1% with appropriate 
buffer. Next, 1 mL of racemic Solution and 19 mL of the 
dilute Vancomycin Solution are placed into Sample chamber 
10. On top of sample chamber 10 is foam column 14, which 
is packed with glass beads 16. Air 18 is blown through 
piping 20, through frit 22 and into sample chamber 10. The 
air bubbles passing through Sample 12 cause a foam to be 
formed. The height of the foam is controlled by the amount 
of air. The foam tends to break-up as it passes through glass 
beads 16 and produces a thin film of liquid that flows down 
the column (i.e. counter current to the foam migration). After 
a steady counter current reflux condition is established, a 
foam fraction is collected in container 24 by increasing the 
flow rate of air 18. One of the enantiomers in the racemic 
Solution is then collected in container 24. 
The concentration of the chiral Selector and racemic 
mixture must be optimized in each case as does pH. 
In this way macrocyclic antibiotics are used to Separate 
enantiomers using absorption bubble technology. 
EXAMPLE 31 
This example illustrates using Teichomycin as a chiral 
Stationary phase. 
Following the procedure in Example 29, above, Teicho 
mycin was used as a Stationary phase to Separate the 
enantiomers identified below. The column was operated in 
the same manner as in Example 29 except as noted below: 
D.L-Penylalanine 
Mobile Phase: 40:60 volume ratio of methyl alcohol and 
Water 
Flow Rate: 1 ml/min. 











Sample Concentration: 2 mg/ml 
d.l-DOPA 
Mobile Phase: 40:60 volume ratio of methyl alcohol and 
Water 
Flow Rate: 1 ml/min. 
Injection Volume: 1 microliter 
Sample Concentration: 5 mg/ml 
2.6-dimethyltyrosine 
Mobile Phase: 20:80 volume ratio of ethyl alcohol to 
Water 
Flow Rate: 1 ml/min. 
Injection Volume: 5 microliters 
Sample Concentration: 2 mg/ml 
It will be understood that the claims are intended to cover 
all changes and modifications of the preferred embodiments 
of the invention herein chosen for the purpose of illustration 
which do not constitute a departure from the Spirit and Scope 
of the invention. 
What is claimed is: 
1. A separation material for Sequentially Separating enan 
tiomers from a fluid Solution containing Said enantiomers 
wherein a fluid containing Said enantiomers comes in con 
tact with Said material to cause Said enantiomers to Sequen 
tially Separate one from another, Said material being a 
macrocyclic antibiotic chemically bonded by a Spacer to a 
Support and Said macrocyclic antibiotic is Selected from the 
group consisting of anSamacrollides, macrollides, macrocy 
clic peptides, polyenes and derivatives thereof, Said macro 
cyclic antibiotic interacting with Said enantiomers to cause 
Sequential Separation by means of more than one of the 
following mechanisms: complexation, charge-charge 
interaction, hydrogen bonding, inclusion in a hydrophobic 
pocket, dipole Stacking, or Steric interaction. 
2. The Separation material of claim 1 wherein Said Support 
is Selected from the group consisting of Silica gel, alumina, 
poly Styrenes, polyurethanes, polyvinyl alcohols, 
polyamides, agarose, cellulose, dextran and linear and 
branched amylose. 
3. The Separation material of claim 1 wherein Said ansa 
macrollides are Selected from the group consisting of naph 
thoguinoid anSamacrollides and benzoquinoid anSamac 
rollides and derivatives thereof. 
4. The Separation material of claim 3 wherein Said naph 
thoguinoid anSamacrollides are Selected from the group 
consisting of Streptovaricins, rifamycins, tolpomycins, 
halomicins, naphthomycins and derivatives thereof. 
5. The separation material of claim 3 wherein said ben 
Zoquinoid anSamacrollides are Selected from the group con 
Sisting of geldanamycin, maytansinoids and derivatives 
thereof. 
6. The Separation material of claim 1 wherein Said mac 
rollides are Selected from the group consisting of 
chalcomycin, methymycin, neomethymycin, erythromycin, 
megalomycin, picromycin, narbomycin, oleandomycin, 
triacetyloleandomycin, carbomycin, Spiramycin, tylosin and 
derivatives thereof. 
7. The Separation material of claim 1 wherein Said mac 
rocyclic peptide is a glycopeptide or derivative thereof. 
8. The separation material of claim 7 wherein said gly 
copeptide is Selected from the group consisting of 
ristomycin, teichomycin, avoparcin, actaplanins, Vancomy 
cin and derivatives thereof. 
9. The separation material of claim 1 wherein said mac 
rocyclic peptides are Selected from the group consisting of 
SporideSmollides, capreomycin, ristomycin, cycloSporins, 
tyrocidine, trioStins, gramicidins, tyrocidines, polymyxins, 
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bacit racins, octapeptins, actinomycins, etamycins, amphote ricin, candicidin, candidin, dermoStatin, 
Vernamycins, enniatins, Valinomycin, thiostrepton, fungichromin, nyStatin and derivatives thereof. 
teichomycin, avoparcin, actaplanins, Vancomycin and 
derivatives thereof. 
10. The separation material of claim 1 wherein said 5 
polyenes are Selected from the group consisting of k . . . . 
